Tetrathiomolybdate (TM) is used in the clinic for the treatment of Wilson's disease by inducing dimerization of the metal-binding domain of the cellular copper efflux protein ATP7B (WLN4) through a unique sulfur-bridged Mo2S6O2 cluster.
[1] Fang T, et al. Nat Commun. 2019 Jan 14;10(1):186.
















